|  |
| --- |
| Alendronic acid (Alendronate) |
| Preparations listed in the Drug tariff **Hover the mouse over the £ sign for DT prices** | [**Part VIIIA (hover the mouse here for more info):**](#PartVIIIA) | **DT price** |
| Alendronic acid 10mg, 70mg tablets  | [**£**](#_Alendronic_acid_(Alendronate)_1) |
| Alendronic acid 70mg effervescent tablets S/F (Binosto) | [**£**](#_Alendronic_acid_(Alendronate)) |
| Alendronic acid 70mg/100ml oral solution unit dose S/F | [**£**](#_Alendronic_acid_(Alendronate)) |
| [**Part VIIIB (hover the mouse here for more info):**](#PartVIIIB) | **DT price** |
| None |  |
| Administration in swallowing difficulties |
| Dissolve Binosto effervescent tablet in 120ml water. Drink once the fizzing has subsided and the tablet has completely dissolved, then drink at least 30ml water. Additional plain water may be taken1.Drink alendronic acid 70mg/100ml oral solution with plain water only2.  |
| Administration in enteral feeding tube |
| Flush with 15ml water, place tablet in the barrel of the syringe with 10ml water and shake gently, flush (unlicensed). Rinse the syringe with 10ml water and flush. Flush the tube with at least 50ml water3. If the patient is on an overnight feed, it may be appropriate to dose in the evening. Enteral feed should be stopped prior to administration for as long as practicable, and should not be re-started for at least 30 minutes after the dose3. Fosamax tablets can also be administered in this fashion (unlicensed) 4.Dissolve one Binosto tablet in 120ml water and administer (unlicensed), then flush with at least 50ml of water3,5. If the patient is on an overnight feed, it may be appropriate to dose in the evening. Enteral feed should be stopped prior to administration for as long as practicable, and should not be re-started for at least 30 minutes after the dose3,5. Please note there is only anecdotal information on administering Binosto via feeding tube4. |
| Comments |
| Alendronate should be taken with water at least 30 minutes before breakfast, medicine or other drinks and the patient should not lie down for at least 30 minutes afterwards. Check the patient has calcium and vitamin D supplementation.Alendronate is contraindicated in patients with oesophageal disease1,2. Rosemont Pharmaceuticals do not have any information on administering alendronic acid 70mg/100ml oral solution via a feeding tube6. |
| References1. Summary of Product Characteristics (SPC) Binosto (Internis Pharmaceuticals) last updated 23/2/2016 [www.medicines.org.uk](http://www.medicines.org.uk) date accessed 6 June 2019
2. SPC. Alendronic acid 70mg oral solution (Rosemont Pharmaceuticals) last updated November 2015 [www.medicines.org.uk](http://www.medicines.org.uk) date accessed 6 June 2019
3. White R and Bradnam V. Handbook of Drug Administration via enteral feeding tubes. 3rd edition, 2015. Pharmaceutical Press
4. Email correspondence on file: Fosamax tablet. (Email reference GB19-04000) Merck Sharpe & Dohme Medicines information. Received 25 April 2019
5. Email correspondence on file: Binosto. (Email reference: MIQ-05242019-1937/MIQ-05242019-1945/MIQ-05242019-1946) Thornton & Ross Medicines information. Received 24 May 2019
6. Email correspondence on file: alendronic acid oral solution. Rosemont Pharmaceuticals Medicines information. Received 10 May 2019
7. Drug Tariff June 2019 <https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff> date accessed 13 June 2019
 |
| **Please note: full instructions should be provided to the person administering the medicine. This is guidance only and should not determine individualised care.** |
| Author: Vicki Kong, QIPP Programme Pharmacist, BHR CCGsApproved by BHR CCGs Area Prescribing sub-Committees: July 2019 |
| Review date: July 2021 | Version: 1 |